GATINEAU (Québec), Competition Bureau
As part its ongoing investigation into BWX Technologies' acquisition of Kinectrics, the Competition Bureau has obtained court orders to gather information from Novartis and certain subsidiaries. Novartis, along with the merged firm, is involved in the manufacture and sale of nuclear medicine products in Canada.
The Bureau is examining whether the transaction is likely to substantially lessen or prevent competition in Canada's nuclear medicine sector. BWX Technologies and Kinectrics provide products and services at various stages of the medical isotope value chain. The investigation is looking into whether the transaction could reduce supply or increase prices for life-saving medical isotopes, which are critical for Canadians seeking certain cancer treatments.
The latest court orders, granted by the Federal Court of Canada, expand the investigation, and require Novartis to provide records and information relevant to the inquiry. This follows the court orders the Bureau obtained for other market participants who are suppliers of inputs used to develop nuclear medical isotopes.
BWX Technologies announced that it closed the transaction on May 20, 2025. The investigation is ongoing and no conclusions have been made at this time.
